Recently, the ArQule’s lead candidate, derazantinib, showed positive preliminary action from a Phase 2 liver cancer study. In addition, ArQule reported that partner Basilea Pharmaceutica (OTC: BPMUF) will team up with Roche (OTCQX: RHHBY) to assess the combination of derazantinib, multi-kinase inhibitor, and atezolizumab for the treatment of urothelial cancer.
ArQule Inc. (ARQL) is a biotechnology company that engaged in finding and developing therapies for cancers and rare diseases. Their mission is to devise, cultivate, and commercialize modern small molecule drugs in order to lengthen the lives of patients. The company